Epigallocatechin-3-gallate  ||| S:0 E:27 ||| FW
attenuates  ||| S:27 E:38 ||| FW
unilateral  ||| S:38 E:49 ||| FW
ureteral  ||| S:49 E:58 ||| FW
obstruction-induced  ||| S:58 E:78 ||| FW
renal  ||| S:78 E:84 ||| FW
interstitial  ||| S:84 E:97 ||| FW
fibrosis  ||| S:97 E:106 ||| FW
in  ||| S:106 E:109 ||| IN
mice  ||| S:109 E:114 ||| NNS
The  ||| S:114 E:118 ||| DT
severity  ||| S:118 E:127 ||| NN
of  ||| S:127 E:130 ||| IN
tubulointerstitial  ||| S:130 E:149 ||| JJ
fibrosis  ||| S:149 E:158 ||| NN
is  ||| S:158 E:161 ||| VBZ
regarded  ||| S:161 E:170 ||| VBN
as  ||| S:170 E:173 ||| IN
an  ||| S:173 E:176 ||| DT
important  ||| S:176 E:186 ||| JJ
determinant  ||| S:186 E:198 ||| NN
of  ||| S:198 E:201 ||| IN
renal  ||| S:201 E:207 ||| JJ
prognosis ||| S:207 E:216 ||| NN
.  ||| S:216 E:218 ||| .
Therapeutic  ||| S:218 E:230 ||| JJ
strategies  ||| S:230 E:241 ||| NNS
targeting  ||| S:241 E:251 ||| VBG
tubulointerstitial  ||| S:251 E:270 ||| JJ
fibrosis  ||| S:270 E:279 ||| NNS
have  ||| S:279 E:284 ||| VBP
been  ||| S:284 E:289 ||| VBN
considered  ||| S:289 E:300 ||| VBN
to  ||| S:300 E:303 ||| TO
have  ||| S:303 E:308 ||| VB
potential  ||| S:308 E:318 ||| JJ
in  ||| S:318 E:321 ||| IN
the  ||| S:321 E:325 ||| DT
treatment  ||| S:325 E:335 ||| NN
of  ||| S:335 E:338 ||| IN
chronic  ||| S:338 E:346 ||| JJ
kidney  ||| S:346 E:353 ||| NN
disease ||| S:353 E:360 ||| NN
.  ||| S:360 E:362 ||| .
This  ||| S:362 E:367 ||| DT
study  ||| S:367 E:373 ||| NN
aims  ||| S:373 E:378 ||| VBZ
to  ||| S:378 E:381 ||| TO
evaluate  ||| S:381 E:390 ||| VB
the  ||| S:390 E:394 ||| DT
protective  ||| S:394 E:405 ||| JJ
effects  ||| S:405 E:413 ||| NNS
of  ||| S:413 E:416 ||| IN
( ||| S:416 E:417 ||| -LRB-
- ||| S:417 E:418 ||| NNP
) ||| S:418 E:419 ||| -RRB-
-epigallocatechin-3-gallate  ||| S:419 E:447 ||| NNP
( ||| S:447 E:448 ||| -LRB-
EGCG ||| S:448 E:452 ||| NNP
) ||| S:452 E:453 ||| -RRB-
,  ||| S:453 E:455 ||| ,
a  ||| S:455 E:457 ||| DT
green  ||| S:457 E:463 ||| JJ
tea  ||| S:463 E:467 ||| NN
polyphenol ||| S:467 E:477 ||| NN
,  ||| S:477 E:479 ||| ,
against  ||| S:479 E:487 ||| IN
renal  ||| S:487 E:493 ||| JJ
interstitial  ||| S:493 E:506 ||| JJ
fibrosis  ||| S:506 E:515 ||| NN
in  ||| S:515 E:518 ||| IN
mice ||| S:518 E:522 ||| NNS
.  ||| S:522 E:524 ||| .
EGCG  ||| S:524 E:529 ||| NNP
was  ||| S:529 E:533 ||| VBD
administrated  ||| S:533 E:547 ||| JJ
intraperitoneally  ||| S:547 E:565 ||| NN
for  ||| S:565 E:569 ||| IN
14  ||| S:569 E:572 ||| CD
days  ||| S:572 E:577 ||| NNS
in  ||| S:577 E:580 ||| IN
a  ||| S:580 E:582 ||| DT
mouse  ||| S:582 E:588 ||| NN
model  ||| S:588 E:594 ||| NN
of  ||| S:594 E:597 ||| IN
unilateral  ||| S:597 E:608 ||| JJ
ureteral  ||| S:608 E:617 ||| JJ
obstruction  ||| S:617 E:629 ||| NN
( ||| S:629 E:630 ||| -LRB-
UUO ||| S:630 E:633 ||| NNP
) ||| S:633 E:634 ||| -RRB-
.  ||| S:634 E:636 ||| .
The  ||| S:636 E:640 ||| DT
results  ||| S:640 E:648 ||| NNS
of  ||| S:648 E:651 ||| IN
our  ||| S:651 E:655 ||| PRP$
histological  ||| S:655 E:668 ||| JJ
examination  ||| S:668 E:680 ||| NN
showed  ||| S:680 E:687 ||| VBD
that  ||| S:687 E:692 ||| IN
EGCG  ||| S:692 E:697 ||| NNP
alleviated  ||| S:697 E:708 ||| NN
glomerular  ||| S:708 E:719 ||| NNS
and  ||| S:719 E:723 ||| CC
tubular  ||| S:723 E:731 ||| JJ
injury  ||| S:731 E:738 ||| NN
and  ||| S:738 E:742 ||| CC
attenuated  ||| S:742 E:753 ||| JJ
renal  ||| S:753 E:759 ||| JJ
interstitial  ||| S:759 E:772 ||| JJ
fibrosis  ||| S:772 E:781 ||| NN
in  ||| S:781 E:784 ||| IN
UUO  ||| S:784 E:788 ||| NNP
mice ||| S:788 E:792 ||| NNS
.  ||| S:792 E:794 ||| .
Furthermore ||| S:794 E:805 ||| RB
,  ||| S:805 E:807 ||| ,
the  ||| S:807 E:811 ||| DT
inflammatory  ||| S:811 E:824 ||| JJ
responses  ||| S:824 E:834 ||| NNS
induced  ||| S:834 E:842 ||| VBN
by  ||| S:842 E:845 ||| IN
UUO  ||| S:845 E:849 ||| NNP
were  ||| S:849 E:854 ||| VBD
inhibited ||| S:854 E:863 ||| CD
,  ||| S:863 E:865 ||| ,
as  ||| S:865 E:868 ||| RB
represented  ||| S:868 E:880 ||| VBN
by  ||| S:880 E:883 ||| IN
decreased  ||| S:883 E:893 ||| JJ
macrophage  ||| S:893 E:904 ||| JJ
infiltration  ||| S:904 E:917 ||| NN
and  ||| S:917 E:921 ||| CC
inflammatory  ||| S:921 E:934 ||| JJ
cytokine  ||| S:934 E:943 ||| JJ
production ||| S:943 E:953 ||| NN
.  ||| S:953 E:955 ||| .
Additionally ||| S:955 E:967 ||| RB
,  ||| S:967 E:969 ||| ,
the  ||| S:969 E:973 ||| DT
expression  ||| S:973 E:984 ||| NN
of  ||| S:984 E:987 ||| IN
type  ||| S:987 E:992 ||| NN
I  ||| S:992 E:994 ||| PRP
and  ||| S:994 E:998 ||| CC
III  ||| S:998 E:1002 ||| NNP
collagen  ||| S:1002 E:1011 ||| NN
in  ||| S:1011 E:1014 ||| IN
the  ||| S:1014 E:1018 ||| DT
kidney  ||| S:1018 E:1025 ||| NN
were  ||| S:1025 E:1030 ||| VBD
reduced  ||| S:1030 E:1038 ||| VBN
by  ||| S:1038 E:1041 ||| IN
EGCG ||| S:1041 E:1045 ||| NNP
,  ||| S:1045 E:1047 ||| ,
which  ||| S:1047 E:1053 ||| WDT
indicated  ||| S:1053 E:1063 ||| VBD
an  ||| S:1063 E:1066 ||| DT
inhibition  ||| S:1066 E:1077 ||| NN
of  ||| S:1077 E:1080 ||| IN
extracellular  ||| S:1080 E:1094 ||| JJ
matrix  ||| S:1094 E:1101 ||| JJ
accumulation ||| S:1101 E:1113 ||| NN
.  ||| S:1113 E:1115 ||| .
EGCG  ||| S:1115 E:1120 ||| NNP
also  ||| S:1120 E:1125 ||| RB
caused  ||| S:1125 E:1132 ||| VBD
an  ||| S:1132 E:1135 ||| DT
up-regulation  ||| S:1135 E:1149 ||| JJ
in  ||| S:1149 E:1152 ||| IN
α-smooth  ||| S:1152 E:1161 ||| JJ
muscle  ||| S:1161 E:1168 ||| NN
actin  ||| S:1168 E:1174 ||| NN
expression  ||| S:1174 E:1185 ||| NN
and  ||| S:1185 E:1189 ||| CC
a  ||| S:1189 E:1191 ||| DT
down-regulation  ||| S:1191 E:1207 ||| JJ
in  ||| S:1207 E:1210 ||| IN
E-cadherin  ||| S:1210 E:1221 ||| JJ
expression ||| S:1221 E:1231 ||| NN
,  ||| S:1231 E:1233 ||| ,
indicating  ||| S:1233 E:1244 ||| VBG
the  ||| S:1244 E:1248 ||| DT
inhibition  ||| S:1248 E:1259 ||| NN
of  ||| S:1259 E:1262 ||| IN
epithelial-to-mesenchymal  ||| S:1262 E:1288 ||| JJ
transition ||| S:1288 E:1298 ||| NN
.  ||| S:1298 E:1300 ||| .
These  ||| S:1300 E:1306 ||| DT
changes  ||| S:1306 E:1314 ||| NNS
were  ||| S:1314 E:1319 ||| VBD
found  ||| S:1319 E:1325 ||| VBN
to  ||| S:1325 E:1328 ||| TO
be  ||| S:1328 E:1331 ||| VB
in  ||| S:1331 E:1334 ||| IN
parallel  ||| S:1334 E:1343 ||| NN
with  ||| S:1343 E:1348 ||| IN
the  ||| S:1348 E:1352 ||| DT
decreased  ||| S:1352 E:1362 ||| JJ
level  ||| S:1362 E:1368 ||| NN
of  ||| S:1368 E:1371 ||| IN
TGF-β1  ||| S:1371 E:1378 ||| NNP
and  ||| S:1378 E:1382 ||| CC
phosphorylated  ||| S:1382 E:1397 ||| JJ
Smad ||| S:1397 E:1401 ||| NNP
.  ||| S:1401 E:1403 ||| .
In  ||| S:1403 E:1406 ||| IN
conclusion ||| S:1406 E:1416 ||| NN
,  ||| S:1416 E:1418 ||| ,
the  ||| S:1418 E:1422 ||| DT
present  ||| S:1422 E:1430 ||| JJ
study  ||| S:1430 E:1436 ||| NN
demonstrates  ||| S:1436 E:1449 ||| VBZ
that  ||| S:1449 E:1454 ||| IN
EGCG  ||| S:1454 E:1459 ||| NNP
could  ||| S:1459 E:1465 ||| MD
attenuate  ||| S:1465 E:1475 ||| VB
renal  ||| S:1475 E:1481 ||| JJ
interstitial  ||| S:1481 E:1494 ||| JJ
fibrosis  ||| S:1494 E:1503 ||| NN
in  ||| S:1503 E:1506 ||| IN
UUO  ||| S:1506 E:1510 ||| NNP
mice ||| S:1510 E:1514 ||| NNS
,  ||| S:1514 E:1516 ||| ,
and  ||| S:1516 E:1520 ||| CC
this  ||| S:1520 E:1525 ||| DT
renoprotective  ||| S:1525 E:1540 ||| JJ
effect  ||| S:1540 E:1547 ||| NN
might  ||| S:1547 E:1553 ||| MD
be  ||| S:1553 E:1556 ||| VB
associated  ||| S:1556 E:1567 ||| VBN
with  ||| S:1567 E:1572 ||| IN
its  ||| S:1572 E:1576 ||| PRP$
effects  ||| S:1576 E:1584 ||| NNS
of  ||| S:1584 E:1587 ||| IN
inflammatory  ||| S:1587 E:1600 ||| JJ
responses  ||| S:1600 E:1610 ||| NNS
alleviation  ||| S:1610 E:1622 ||| NN
and  ||| S:1622 E:1626 ||| CC
TGF-β ||| S:1626 E:1631 ||| JJ
/ ||| S:1631 E:1632 ||| FW
Smad  ||| S:1632 E:1637 ||| FW
signaling  ||| S:1637 E:1647 ||| FW
pathway  ||| S:1647 E:1655 ||| FW
inhibition ||| S:1655 E:1665 ||| FW
.  ||| S:1665 E:1667 ||| .
